Epstein-Barr Virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments
Marine Baron,Karim Labreche,Marianne Veyri,Nathalie Désiré,Amira Bouzidi,Fatou Seck-Thiam,Frédéric Charlotte,Alice Rousseau,Véronique Morin,Cécilia Nakid-Cordero,Baptiste Abbar,Alberto Picca,Marie Le Cann,Noureddine Balegroune,Nicolas Gauthier,Ioannis Theodorou,Mehdi Touat,Véronique Morel,Franck Bielle,Assia Samri,Agusti Alentorn,Marc Sanson,Damien Roos-Weil,Corinne Haioun,Elsa Poullot,Anne Langlois De Septenville,Frédéric Davi,Amélie Guihot,Pierre-Yves Boelle,Véronique Leblond,Florence Coulet,Jean-Philippe Spano,Sylvain Choquet,Brigitte Autran,IDeATIon Study group
DOI: https://doi.org/10.3324/haematol.2023.284332
2024-06-06
Haematologica
Abstract:Non-Hodgkin lymphomas (NHL) commonly occur in immune-deficient (ID) patients, both HIV-infected and transplanted, and are often EBV-driven with cerebral localization, raising the question of tumor immunogenicity, a critical issue for treatment responses. We investigated the immunogenomics of 68 lymphoproliferative disorders from 51 ID (34 posttransplant, 17 HIV+) and 17 immunocompetent patients. Overall, 72% were Large B Cells Lymphoma (LBCL) and 25% were primary central-nervous-system lymphoma (PCNSL) while 40% were EBV-positive. Tumor whole-exome and RNA sequencing, along with a bioinformatics pipeline allowed analysis of tumor mutational burden (TMB), tumor landscape and microenvironment (TME) and prediction of tumor neoepitopes. Both TMB (2.2 vs 3.4/Mb, p=0.001) and neoepitopes numbers (40 vs 200, p=0.00019) were lower in EBVpositive than in EBV-negative NHL, regardless of the immune status. In contrast both EBV and the immune status influenced the tumor mutational profile, with HNRNPF and STAT3 mutations exclusively observed in EBV-positive and ID NHL, respectively. Peripheral blood T-cell responses against tumor neoepitopes were detected in all EBV-negative cases but in only half EBV-positive ones, including responses against IgH-derived MHC-class-II restricted neoepitopes. The TME analysis showed higher CD8 T cell infiltrates in EBVpositive vs EBV-negative NHL, together with a more tolerogenic profile composed of Tregs, type-M2 macrophages and an increased expression of negative immune-regulators. Our results highlight that the immunogenomics of NHL in patients with immunodeficiency primarily relies on the tumor EBV status, while T cell recognition of tumor- and IgH-specific neoepitopes is conserved in EBV-negative patients, offering potential opportunities for future T cell-based immune therapies.
hematology